scholarly journals Pattern of muscle strength improvement after intravenous immunoglobulin therapy in multifocal motor neuropathy

2021 ◽  
Author(s):  
Jaap N.E. Bakers ◽  
Ruben P.A. Eijk ◽  
Leonard H. Berg ◽  
Johanna M. A. Visser‐Meily ◽  
Anita Beelen
Keyword(s):  
Muscle Strength ◽  
Intravenous Immunoglobulin ◽  
Immunoglobulin Therapy ◽  
Multifocal Motor Neuropathy ◽  
Motor Neuropathy ◽  
Intravenous Immunoglobulin Therapy ◽  
Strength Improvement

scholarly journals High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy

Neurology ◽  
1993 ◽  
Vol 43 (3, Part 1) ◽  
pp. 537-537 ◽  
Author(s):  
E. Nobile-Orazio ◽  
N. Meucci ◽  
S. Barbieri ◽  
M. Carpo ◽  
G. Scarlato
Keyword(s):  
Intravenous Immunoglobulin ◽  
Immunoglobulin Therapy ◽  
Multifocal Motor Neuropathy ◽  
High Dose ◽  
Motor Neuropathy ◽  
Intravenous Immunoglobulin Therapy

scholarly journals How We Treat Autoimmune Small Fiber Polyneuropathy with Immunoglobulin Therapy

2018 ◽  
Vol 80 (5-6) ◽  
pp. 304-310 ◽  
Author(s):  
Jill R. Schofield ◽  
Kamal R. Chemali
Keyword(s):  
Intravenous Immunoglobulin ◽  
Chronic Inflammatory Demyelinating Polyneuropathy ◽  
Immunoglobulin Therapy ◽  
Multifocal Motor Neuropathy ◽  
Motor Neuropathy ◽  
Intravenous Immunoglobulin Therapy ◽  
Small Fiber ◽  
Immune Mediated ◽  
Inflammatory Demyelinating Polyneuropathy ◽  
Significant Efficacy

Intravenous immunoglobulin therapy is FDA approved for the immune-mediated peripheral nerve disorders Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. Immunoglobulin therapy has been used increasingly with significant efficacy in the treatment of patients with disabling autoimmune forms of dysautonomia, which are most often small fiber (autonomic and/or sensory) polyneuropathies. It is recognized by most who treat these disorders, however, that patients with autonomic dysfunction treated with intravenous immunoglobulin therapy develop aseptic meningitis or severe lingering headache more frequently than other patient populations when this therapy is dosed in the traditional fashion. We discuss our combined 27 years of experience with the use of immunoglobulin and other immune modulatory therapy in patients with autoimmune small fiber polyneuropathy.

The Long-term Treatment of Multifocal Motor Neuropathy with Intravenous Immunoglobulin

2012 ◽  
Vol 7 (2) ◽  
pp. 128 ◽  
Author(s):  
Leonard H van den Berg ◽  
Keyword(s):  
Muscle Strength ◽  
Intravenous Immunoglobulin ◽  
Initial Response ◽  
Multifocal Motor Neuropathy ◽  
Term Treatment ◽  
Response To Treatment ◽  
Motor Neuropathy ◽  
Double Blind ◽  
Long Term Treatment

Multifocal motor neuropathy (MMN) is a rare, purely motor neuropathy. It is a progressive disorder, most patients eventually developing severe fatigue and weakness in the arm muscles that severely impair daily functioning and quality of life. Unlike other motor neuropathies such as motor neurone disease, MMN is treatable with regular infusions of intravenous immunoglobulin (IVIg). Four double-blind, randomised, placebo-controlled studies have shown that in the short term, IVIg significantly improves muscle strength and disability in more than 70 % of patients. The 11 observational studies reviewed in this article confirm that long-term maintenance treatment with IVIg maintains clinical improvement compared to pre-treatment baseline in most patients. Infusions are generally well tolerated, but regular monitoring and re-evaluation of the IVIg maintenance regimen is essential, as most patients need progressive increases in dosage or reduced intervals between infusions to maintain their response to treatment. In the absence of accepted predictive markers, maintenance IVIg should be individualised, based on each patient’s initial response, disability and the interval between the first infusion and decline in muscle strength.

Sign in / Sign up

Export Citation Format

Share Document